FACULTY
Diana V. Do, MD
Vice Chair of Clinical Affairs
Professor of Ophthalmology
Clinic Chief of Ophthalmology for Stanford Health Care
Byers Eye Institute
Stanford University School of Medicine
Stanford, CT
PROGRAM OVERVIEW
This enduring activity focuses on the use of next-generation therapies such as gene therapy, biosimilars, advanced delivery systems, artificial intelligence, and advancements in pharmacological treatments, including new molecular targets and therapeutic formulations for the management of patients with diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion. Listen to a retina expert explain the rationale behind these new therapies, as well as the clinical trial data regarding their safety, efficacy, and mechanisms of action to expand treatment options and potentially improve visual outcomes in patients with retinal vascular conditions.
TARGET AUDIENCE
This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, pharmacists, and other healthcare providers who manage patients with diabetic retinopathy, age-related macular degeneration, and/or retinal vein occlusion.
LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:
- Determine the rationale for the use of next-generation therapies such as gene therapy, biosimilars, advanced delivery systems, artificial intelligence, and pharmacological treatments targeting new molecular pathways for the management of patients with diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion
- Assess the safety, efficacy, and mechanisms and rationale for next-generation therapies for diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion
- Evaluate recent clinical data of next-generation therapeutic strategies for DR, AMD or RVO
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Diana V. Do has received consulting fees from Apellis, Iveric Bio, Kodiak Sciences, Genentech, Regeneron, Kriya Therapeutics, and Boehringer Ingelheim. Dr. Do has conducted contracted research for Regeneron, Kriya Therapeutics, and Boehringer Ingelheim. In addition, Dr. Do has ownership in Kodiak Sciences.
All relevant financial relationships have been mitigated.
CME Content Review
‘The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Chimene Richa, MD, Medical Director of Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures
- Participate in the enduring activity
- Complete pre-and-post surveys and evaluation
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 08, 2023
EXPIRATION DATE: June 08, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.